Entera Bio (STU:5DT) Institutional Ownership: 0.06% (As of Aug. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:5DT Entera Bio Ltd STU:5DT
37 GF Score
Price €2.48
GF Value €0.21
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Entera Bio Institutional Ownership?

Entera Bio STU:5DT +0.81% 37 Institutional Ownership is 0.06% as of Aug. 18, 2026. GuruFocus rates STU:5DT with a GF Score™ of 37/100 and a GF Value™ of €0.21 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Entera Bio's institutional ownership is 0.06%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Entera Bio's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Entera Bio's Float Percentage Of Total Shares Outstanding is 96.14%.

Entera Bio Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Entera Bio's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entera Bio Institutional Ownership Chart

Entera Bio Historical Data

The historical data trend for Entera Bio can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-06-30 2026-07-31
Institutional Ownership 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.06 0.06 0.06
STU:5DT
37GF Score
Entera Bio Ltd STU:5DT
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Entera Bio Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.06% mean?
Entera Bio (STU:5DT) has a Institutional Ownership of 0.06% as of Aug. 18, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Entera Bio and its competitors.
Is Entera Bio's Institutional Ownership too high?
Entera Bio's current Institutional Ownership is 0.06%. Overall, Entera Bio has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Entera Bio's Institutional Ownership compare to ICCC and BDTX?
Entera Bio's Institutional Ownership of 0.06% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Entera Bio and its competitors. Entera Bio's current Institutional Ownership is 0.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entera Bio stock overvalued right now?
Based on GuruFocus' analysis, Entera Bio (STU:5DT) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.21, compared to a current price of €2.48 — trading 1081% above its estimated fair value. The current Institutional Ownership is 0.06%. Entera Bio's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Entera Bio (STU:5DT), the current Institutional Ownership is 0.06% as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Entera Bio (STU:5DT) Overvalued in 2026?

Based on GuruFocus' analysis, Entera Bio stock appears to be overvalued. The current stock price of €2.48 is trading 1081% above its estimated GF Value™ of €0.21. GuruFocus considers Entera Bio to be Significantly Overvalued.

Key valuation signals for STU:5DT:

  • Institutional Ownership: 0.06%
  • GF Value™: €0.21 vs. price of €2.48 (1081% above fair value)
  • GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the STU:5DT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Entera Bio Business Description

Other Exchanges ENTX:USA
Address Kiryat Hadassah, Minrav Building - Fifth Floor, Hadassah Bio Park, Jerusalem, ISR, 9112002
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
37GF Score

Get the complete analysis for STU:5DT

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.48
Price
€0.21
GF Value